How Do You Get Tuberculosis: Causes and Spread

Tuberculosis spreads almost exclusively through the air. When a person with active TB in their lungs coughs, speaks, sings, or even breathes, they release tiny particles called droplet nuclei that carry the bacterium Mycobacterium tuberculosis. Someone nearby inhales those particles, and if the bacteria reach the deep lung tissue, an infection can take hold. The story after that first breath, though, is far more complicated than most people realize, because the vast majority of those who become infected never actually get sick.

How TB Travels Through the Air

The critical detail about TB transmission is the size of the particles involved. Regular respiratory droplets from a cough are relatively large and fall to the ground quickly. Droplet nuclei, by contrast, are so small that they can remain suspended in the air for hours, drifting on normal air currents. Classic experiments in the 1950s first demonstrated that these airborne particles, not surface contact or large droplets, are the primary route of human-to-human TB transmission.¹ That finding has held up for decades and remains the foundation of TB control strategies today.

You cannot catch TB from shaking hands, sharing utensils, or touching a doorknob. The bacterium needs to reach the deepest parts of the lung, the alveoli, to establish infection. Only particles small enough to bypass the nose, throat, and upper airways can get there. This is why proximity and shared air matter so much: sitting next to someone with active TB on a long bus ride carries real risk, while brief passing contact in an open outdoor space carries almost none.

One thing that surprises people is how long the bacteria can persist outside a human host. Research has found both experimental and epidemiological evidence that M. tuberculosis can remain viable in natural and built environments for months to years after being expelled by an infectious person.¹ In practice, direct airborne person-to-person transmission in enclosed spaces remains far and away the dominant route of infection, but the environmental durability of the organism helps explain why certain buildings and institutions become hotspots.

What Happens Once the Bacteria Reach Your Lungs

When M. tuberculosis lands in the alveoli, the first immune cells to encounter it are alveolar macrophages, which are essentially the lungs’ resident security team.² Macrophages are supposed to engulf and destroy invaders, and they do swallow TB bacteria readily. The problem is what happens next. The bacterium has evolved a remarkable trick: it prevents the compartment it sits in from maturing into the acidic, enzyme-filled killing chamber it would normally become.³ In effect, the bacteria hijack their own prison, turning it into a comfortable living space where they can survive and multiply.

From these initial footholds in the lung, the bacteria can travel through the lymphatic system and bloodstream to other parts of the body, a process that can seed TB in bones, kidneys, the brain, lymph nodes, and other organs.⁴ This spread beyond the lungs is called extrapulmonary tuberculosis, and while it is less common than the pulmonary form, it can be harder to diagnose because its symptoms mimic many other conditions.

Latent TB and Why Most Infected People Never Get Sick

Here is the statistic that reframes the entire disease: roughly 90 to 95 percent of people who become infected with M. tuberculosis never develop active, symptomatic TB.⁵ Their immune systems wall off the bacteria inside small clusters of immune cells called granulomas, keeping the infection contained indefinitely. These people are classified as having latent TB infection. They feel perfectly healthy, have no symptoms, and cannot spread the disease to others.

Latent infection is identified not by symptoms but by immune evidence: either a positive tuberculin skin test or a blood test showing that your immune cells recognize TB-specific proteins.⁵ A positive result means you have been exposed and your body mounted a response, but it says nothing about whether you will ever get sick. The distinction between latent infection and active disease is one of the most important concepts in TB medicine, and it is often misunderstood. Being infected is not the same as having tuberculosis. Many people carry the bacteria for their entire lives with no consequences.

That said, latently infected people are a vast reservoir. The remaining 5 to 10 percent who do progress to active TB may do so within months of infection or decades later, depending on what happens to their immune system in the interim.⁶

What Tips the Balance Toward Active Disease

If the immune system is what keeps latent TB in check, then anything that weakens immunity can allow the bacteria to escape containment. Several specific conditions stand out as major drivers of progression from latent to active TB.

HIV

HIV is the single largest risk factor for turning a latent TB infection into active disease. The virus doesn’t simply reduce the number of CD4 T cells that help fight TB; it impairs the quality of the TB-specific immune response. Research has shown that HIV infection reduces the production of key protective immune signals by TB-specific CD4 and CD8 T cells and suppresses the broader inflammatory response that helps contain the bacteria.⁷ The relationship runs both ways: active TB also depletes HIV-specific immune cells, potentially accelerating HIV progression.⁸ This vicious cycle makes TB-HIV co-infection one of the deadliest pairings in infectious disease.

Interestingly, animal research using a closely related virus has shown that the mere loss of CD4 T cells during latent TB is not enough on its own to trigger reactivation. Instead, the chronic immune activation and disrupted immune balance caused by the virus appear to be the more important factors.⁹ This helps explain why even people with relatively preserved CD4 counts can develop TB if they are living with HIV.

Diabetes

Type 2 diabetes has emerged as a major TB risk factor, especially in countries where both conditions are common. Diabetes increases susceptibility to TB, worsens disease severity, and slows the response to treatment.¹⁰ The connection is immunological: people with TB infection and type 2 diabetes show a reduced ability to inhibit bacterial growth and produce lower levels of the protective immune signals needed to keep TB contained.¹¹ As the global diabetes epidemic expands, this overlap is becoming an increasingly important public health concern, particularly in South and Southeast Asia and sub-Saharan Africa.

Malnutrition and Smoking

Undernutrition weakens virtually every arm of the immune response and is one of the most significant drivers of TB worldwide, particularly in low-income settings.¹² In India and Southeast Asia, malnutrition is considered a leading factor in the ongoing TB burden.¹³

Tobacco smoking roughly doubles the risk of active TB and may account for up to a fifth of all active TB cases globally.¹⁴ The mechanism is not just about damaging the lungs in a general sense. Smoking pulls immature inflammatory cells from the bloodstream into the airways. These cells are less capable of killing TB bacteria and actually allow faster bacterial growth inside them, effectively creating a more hospitable environment for the pathogen. The risk climbs with heavier and longer smoking: one study found that heavy smokers had odds of TB roughly three and a half times higher than nonsmokers, and the risk increased in a dose-dependent fashion with both the number of cigarettes per day and years of smoking.¹⁵

Other well-established risk factors include immunosuppressive medications (such as anti-TNF therapies used for rheumatoid arthritis and similar conditions), chronic kidney disease, organ transplant, heavy alcohol use, and aging. Doctors routinely screen for latent TB before starting anti-TNF drugs because these therapies can unleash dormant infections.¹⁶

Where Transmission Risk Is Highest

Because TB is airborne, the physical environment matters enormously. Two factors dominate: ventilation and crowding. A poorly ventilated room concentrates airborne bacteria, while a crowded room increases the chance that an infectious person is present and that others will inhale their exhaled particles.

A study of a TB outbreak in underventilated university buildings found that improving ventilation to keep carbon dioxide below 1,000 parts per million was associated with a 97 percent decrease in TB incidence among contacts, after accounting for other interventions.¹⁷ That is a striking number, and it underscores how central air quality is to TB control. Systematic reviews have also found that overcrowded housing directly increases TB exposure, transmission, and even drug resistance, partly because crowded homes tend to also have poor ventilation and limited sunlight.¹⁸

Research comparing different real-world settings has found that estimated infection risk can be higher in minibus taxis and trains than in shops or bars, reflecting the combination of tight quarters, limited airflow, and prolonged proximity to other passengers.¹⁹ Health clinics can also pose elevated risk, even when ventilation is adequate, simply because so many people pass through them, including people who may not yet know they have TB.

Prisons and Institutional Settings

Prisons are among the highest-risk environments for TB worldwide. They combine nearly every risk factor into one setting: overcrowding, poor ventilation, malnutrition, high rates of HIV, substance use, smoking, and limited access to healthcare.²⁰ TB rates in prison populations in many countries are orders of magnitude higher than in the general community. The problem extends beyond prison walls: incarcerated people eventually return to their communities, and without proper diagnosis and treatment during detention, they can carry active TB with them.

Other congregate settings that carry elevated risk include homeless shelters, long-term care facilities, refugee camps, and mining operations. Healthcare workers also face higher occupational exposure, particularly in settings with high TB prevalence and inadequate infection control. Natural ventilation and upper-room ultraviolet germicidal irradiation are among the most cost-effective environmental controls for these settings.²¹

TB from Animals

While nearly all human TB comes from breathing in bacteria expelled by other humans, there is a second, less common route. Mycobacterium bovis, a close relative of the bacterium that causes human TB, infects cattle and can pass to humans through unpasteurized milk and dairy products.²² This zoonotic form of TB is a recognized public health risk in low-resource, endemic regions where pasteurization is inconsistent and people live in close contact with livestock.²³

In countries with well-established pasteurization and cattle testing programs, zoonotic TB is rare. But in parts of sub-Saharan Africa, South Asia, and Latin America, it remains a meaningful contributor to the TB burden, particularly in rural communities. M. bovis infection in humans is clinically similar to standard TB and is treated with most of the same drugs, though it is naturally resistant to pyrazinamide, one of the first-line medications.

What BCG Vaccination Can and Cannot Do

The BCG vaccine, one of the most widely administered vaccines in history, is given to infants in most countries with significant TB burden. It works well at preventing severe forms of TB in young children, particularly disseminated and meningeal TB, which can be fatal. A large meta-analysis of individual patient data found that BCG significantly protected against pulmonary TB in children younger than three but showed no significant protection against extrapulmonary TB overall.²⁴

The major limitation is that BCG’s protective effect fades with age. It does not reliably prevent adult pulmonary TB, which is the form responsible for most transmission. This is why countries with high BCG coverage still have high TB rates: the vaccine protects the most vulnerable young children from dying of TB, but it does not break the chain of transmission among adults. Several candidate vaccines aiming to protect adolescents and adults are in clinical trials, and the field is cautiously optimistic that at least one may prove effective in the coming years.

Contact Tracing and Finding Infections Early

Because TB spreads through prolonged close contact, one of the most effective public health strategies is tracing the contacts of a newly diagnosed patient. The goal is to identify people who may have been infected before they develop active disease and become infectious themselves. In low-prevalence countries, this is standard practice: once a case is identified, public health workers systematically screen household members, coworkers, and other close contacts.²⁵

Children living with a TB patient are especially vulnerable, and contact investigation combined with preventive therapy has proven effective at interrupting transmission in households.²⁶ Preventive therapy, typically a course of isoniazid taken for several months, can clear latent infection before it has the chance to progress. The challenge is implementation: in high-burden settings, the resources and infrastructure for systematic contact tracing are often limited.

Screening itself has evolved. The traditional tuberculin skin test has been joined by blood-based tests that measure immune cell responses to TB-specific proteins. These blood tests tend to correlate better with actual TB risk, particularly in people who have received the BCG vaccine, since BCG can cause a false-positive skin test but does not affect the blood tests.¹⁶ For people at high risk, such as those about to start immunosuppressive medications, combining both a blood test and a skin test may offer the most thorough screening.

Genetic Susceptibility

Not everyone exposed to TB under the same conditions faces the same risk. Twin studies and family clustering patterns have long suggested that genetics plays a role in who gets infected and who progresses to disease. More recently, researchers have begun identifying specific human gene variants that influence TB outcomes, including rare mutations that cause severe TB susceptibility inherited in a straightforward pattern.²⁷ For most people, susceptibility is not driven by a single gene but by the combined effect of many common variants, each contributing a small amount.

The practical upshot is modest for now. Genetic testing cannot yet tell an individual whether they will develop active TB. But understanding the genetic architecture of susceptibility is shaping vaccine development and may eventually help target preventive therapy to the people most likely to benefit. The field is still early, but the direction of research is toward personalized risk assessment that accounts for both immune status and genetic background.